

Product Data Sheet

Product Name: Delamanid

Cat. No.: GC19122

Chemical Properties

Cas. No. 681492-22-8

SMILES FC(F)(F)OC1=CC=C(OC2CCN(C3=CC=C(OC[C@@]4(C)CN5C(O4)=NC([N+])([O-])=O)=C5)C=C3)CC2)C=C1


Formula $C_{25}H_{25}F_3N_4O_6$ M.Wt 534.48

Solubility DMSO : ≥ 50 mg/mL (93.55 mM); Water : < 0.1 mg/mL (insoluble) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesis of mucolic acids, crucial component of the cell wall of the Mycobacterium tuberculosis complex. In vitro: inhibits the synthesis of mucolic acids, crucial component of the cell wall of the Mycobacterium tuberculosis complex.[1] In in-vitro studies, delamanid shows more potent antibacterial activity against drug-susceptible and drug-resistant strains of M. tuberculosis.[2] Delamanid does not affect rifampin,

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

pyrazinamide, and isoniazid exposure; the ethambutol AUC_T and C_{max} values are about 25% higher with delamanid coadministration. [3] In vivo: Twice-daily oral dosing of delamanid at 30 mg kg⁻¹ for 5 days resulted in sterile cures in a mouse model of VL. [4]

References:

- [1]. Sotgiu G et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther. 2015 Mar;13(3):305-15.
- [2]. Xavier AS et al. Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014 Jul;5(3):222-4
- [3]. Mallikaarjun S et al. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5976-85.
- [4]. Patterson S et al. The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. Elife. 2016 May 24;5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA